The supply price of Bharat Biotech's COVID-19 vaccine Covaxin to the central government at Rs 150 per dose is not sustainable in the long run, the vaccine maker said on Tuesday.
The Centre's supplying price is pushing the pricing structure for the private sector upward.
"Fundamental business reasons ranging from low procurement volumes, high distribution costs and retail margins among few others contribute to higher pricing of Covaxin," Bharat Biotech said justifying the higher price when compared to other COVID-19 vaccines available for the private sector in India.
"The supply price of Covaxin to the government of India at Rs 150 / dose, is a non-competitive price and clearly not sustainable in the long run. Hence a higher price in private markets is required to offset part of the costs," Bharat Biotech said in a statement.
Bharat Biotech has so far invested over Rs 500 crores at risk from its own resources for product development, clinical trials and setting up of manufacturing facilities for Covaxin, it added.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
Bharat Biotech Unveils Next-Gen Oral Cholera Vaccine To Address Global Health Gaps Bharat Biotech Launches Oral Cholera Vaccine After Successful Phase 3 Trial Bharat Biotech Adds Top Medical Body ICMR As Co-Owner Of Covid Vaccine Patent "Go Falcon. Go GSAT-20": SpaceX Successfully Launches Indian Satellite Why Donald Trump's Cabinet Choices Are Giving Pakistan Sleepless Nights Supreme Court Asks About Delhi Construction Ban. Lawyer's Reply Stuns Judge Trump Picks Sean Duffy, Former Congressman, As Transportation Secretary G20 Leaders Fail To Break UN Climate Talks Deadlock Donald Trump Expected To Attend Musk's SpaceX Starship Launch: Report Track Latest News Live on NDTV.com and get news updates from India and around the world.